Pharmaceutical, Clinical & Drug-Development Applications

We help Pharma Companies

Make Better Decisions

AIQ's software technologies can help pharmaceutical companies to evaluate novel therapies faster and with fewer participants, reducing costs and expediting clinical trials.

Learn More
Information on this page is intended for research use only. Not all applications and/or claims listed are currently cleared for use in treatment of patients. TRAQinform IQ software has been cleared by the FDA for clinical use under 510(k) K173444.
Benefit 01—

Consistent and Comprehensive Treatment Response Assessment for each Lesion and organ

Intra-patient heterogeneity of treatment response drives clinical outcomes

Learn more

115 non-small cell lung cancer (NSCLC) patients undergoing chemoradiotherapy imaged with FDG PET/CT at baseline and post-treatment

Clinical outcome

Each lesion was quantified and matched between timepoints using TRAQinform IQ technology. Heterogeneity of response among individual lesions correlates to overall clinical outcome.

Figure: Each bar on chart represents an individual patient showing how each of their lesions are responding to treatment. Each lesion is detected, quantified and categorized as new, progressing, stable, partially responding or completely responding.

Benefit 02—

Highly Sensitive and Rapid Quantification of Pharmacodynamic Effects using Fewer Patients

Introducing a leading-edge solution to better predict treatment response, giving robust and significant data with smaller cohorts

Learn more

 AIQ Score is an all-inclusive patient lesion analytics metric. It is calculated by using a proprietary AI algorithm that produces a single numeric value which predicts treatment response at the patient level. This multi-faceted metric has been validated across multiple large data sets.

See the validation data

The chart above indicates a prediction of a individual patient's clinical outcome compared to a population.

Benefit 03—

Earlier Determination and Prediction of Treatment Toxicity

Learn more

Automatic Organ Segmentation


Retrospective 57 patient Phase I/II study comparing AIQ technology to experienced reader for evaluating heterogeneous system amyloid build up in multiple organs.

Clinical outcome

“This approach will significantly impact the ease of use and improve accuracy of image interpretation that will ultimately benefit clinical management of patients with amyloidosis.”

Assess Organ-Specific Toxicity: Immunotherapy Applications


Study of 35 melanoma patients in ICI therapy. All patients received 3 FDG PET/CT scans. Changes in SUV uptake were compared between healthy patients and those who developed colitis.

Clinical outcome

AIQ predicted which patients would develop colitis 50 days prior to actual diagnosis.

Assess Organ-Specific Toxicity: Theranostic Applications


Study of 35 patients with metastatic GEP-NETs treated with Lutathera receiving GA-DOTATATE PET/CT

Clinical outcome

Early decrease in bone marrow SUV correlates to decrease in platelet count. Baseline SUV identified patients with increase in creatinine levels.

Benefit 04—

Optimize Clinical Trial Participant Selection for Prospective STudies

Learn more
  • Identify participants with high heterogeneity of treatment responses
  • Predict optimal vs. suboptimal responders using AIQ Score
  • Re-randomize  participants for alternative therapies
  • Create customized models to refine enrollment criteria
  • Evaluate  participants level dosage effectiveness

A valued partner for your studies

AIQ Collaboration

AIQ's collaboration consist of a workflow that is simple and easy to implement with no interruptions. We pride ourselves on building a partnership that up holds our company's values and value proposition. These workflows work whether you are running a single or multi-site study. We also partner with CROs to acquire imaging data.
Contact Us

What questions do you have?

Drop us a line and learn more about AIQ Solutions.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.